세계의 카르글루민산 시장 성장, 규모, 동향 분석 - 제형, 유통 채널, 지역별 전망, 경쟁 전략, 부문 예측(-2034년)

Carglumic Acid Market Introduction and Overview

According to SPER market research, 'Global Carglumic Acid Market Size- By Dosage Form, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Carglumic Acid Market is predicted to reach 309.94 million by 2034 with a CAGR of 7.69%.

Carglumic acid is formed from N-acetyl glutamate and aids in ammonia elimination and detoxification by activating the first enzyme in the urea cycle. This medicine is particularly useful in the treatment of rare disorders such as propionic academia and methyl-malonic academia, which are autosomal recessive and frequently necessitate lifetime medical therapy to preserve normal health.

Restraints: The use of carglumic acid has been restricted by the high cost of acquiring raw materials, the increased capital required for processing the finished product, and certain negative consequences linked to carglumic acid treatments. Furthermore, rising research and development costs, combined with the high cost of medicine, have increased the cost of overall production, prompting customers to seek alternatives.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Dosage Form, By Distribution Channel

Regions covered

North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered

Apothecon Pharmaceuticals Pvt. Ltd, Recordati Rare Diseases Inc, Manus Aktteva Biopharma LLP, Dipharma Francis S.r.l, NURAY CHEMICALS, NOVITIUM PHARMA LLC, Suven Life Sciences Limited, Biophore India Pharmaceuticals Pvt Ltd, Rhyme Organics and Chemicals Ltd, Aktteva Biopharma LLP.

Global Carglumic Acid Market Segmentation:

By Dosage Form: Based on the Dosage Form, Global Carglumic Acid Market is segmented as; Orally Disintegrating Tablets, Dispersible Tablets.

By Distribution Channel: Based on the Distribution Channel, Global Carglumic Acid Market is segmented as; Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

1.Introduction

• 1.1.Scope of the report
• 1.2.Market segment analysis

2.Research Methodology

• 2.1.Research data source
  • 2.1.1.Secondary Data
  • 2.1.2.Primary Data
  • 2.1.3.SPER's internal database
  • 2.1.4.Premium insight from KOL's
• 2.2.Market size estimation
  • 2.2.1.Top-down and Bottom-up approach
• 2.3.Data triangulation

3.Executive Summary

4.Market Dynamics

• 4.1.Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1.Drivers
  • 4.1.2.Restraints
  • 4.1.3.Opportunities
  • 4.1.4.Challenges

5.Market variable and outlook

• 5.1.SWOT Analysis
  • 5.1.1.Strengths
  • 5.1.2.Weaknesses
  • 5.1.3.Opportunities
  • 5.1.4.Threats
• 5.2.PESTEL Analysis
  • 5.2.1.Political Landscape
  • 5.2.2.Economic Landscape
  • 5.2.3.Social Landscape
  • 5.2.4.Technological Landscape
  • 5.2.5.Environmental Landscape
  • 5.2.6.Legal Landscape
• 5.3.PORTER's Five Forces
  • 5.3.1.Bargaining power of suppliers
  • 5.3.2.Bargaining power of buyers
  • 5.3.3.Threat of Substitute
  • 5.3.4.Threat of new entrant
  • 5.3.5.Competitive rivalry
• 5.4.Heat Map Analysis

6.Competitive Landscape

• 6.1.Global Carglumic Acid Market Manufacturing Base Distribution, Sales Area, Product Type
• 6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Carglumic Acid Market

7.Global Carglumic Acid Market, By Dosage Form (USD Million) 2021-2034

• 7.1.Orally Disintegrating Tablets
• 7.2.Dispersible Tablets
• 7.3.Others

8.Global Carglumic Acid Market, By Distribution Channel (USD Million) 2021-2034

• 8.1.Hospital Pharmacies
• 8.2.Retail Pharmacies
• 8.3.Online Pharmacies

9.Global Carglumic Acid Market, (USD Million) 2021-2034

• 9.1.Global Carglumic Acid Market Size and Market Share

10.Global Carglumic Acid Market, By Region, (USD Million) 2021-2034

• 10.1.Asia-Pacific
  • 10.1.1.Australia
  • 10.1.2.China
  • 10.1.3.India
  • 10.1.4.Japan
  • 10.1.5.South Korea
  • 10.1.6.Rest of Asia-Pacific
• 10.2.Europe
  • 10.2.1.France
  • 10.2.2.Germany
  • 10.2.3.Italy
  • 10.2.4.Spain
  • 10.2.5.United Kingdom
  • 10.2.6.Rest of Europe
• 10.3.Middle East and Africa
  • 10.3.1.Kingdom of Saudi Arabia
  • 10.3.2.United Arab Emirates
  • 10.3.3.Qatar
  • 10.3.4.South Africa
  • 10.3.5.Egypt
  • 10.3.6.Morocco
  • 10.3.7.Nigeria
  • 10.3.8.Rest of Middle-East and Africa
• 10.4.North America
  • 10.4.1.Canada
  • 10.4.2.Mexico
  • 10.4.3.United States
• 10.5.Latin America
  • 10.5.1.Argentina
  • 10.5.2.Brazil
  • 10.5.3.Rest of Latin America

11.Company Profile

• 11.1.Apothecon Pharmaceuticals Pvt. Ltd
  • 11.1.1.Company details
  • 11.1.2.Financial outlook
  • 11.1.3.Product summary
  • 11.1.4.Recent developments
• 11.2.Recordati Rare Diseases Inc
  • 11.2.1.Company details
  • 11.2.2.Financial outlook
  • 11.2.3.Product summary
  • 11.2.4.Recent developments
• 11.3.Manus Aktteva Biopharma LLP
  • 11.3.1.Company details
  • 11.3.2.Financial outlook
  • 11.3.3.Product summary
  • 11.3.4.Recent developments
• 11.4.Dipharma Francis S.r.l
  • 11.4.1.Company details
  • 11.4.2.Financial outlook
  • 11.4.3.Product summary
  • 11.4.4.Recent developments
• 11.5.NURAY CHEMICALS
  • 11.5.1.Company details
  • 11.5.2.Financial outlook
  • 11.5.3.Product summary
  • 11.5.4.Recent developments
• 11.6.NOVITIUM PHARMA LLC
  • 11.6.1.Company details
  • 11.6.2.Financial outlook
  • 11.6.3.Product summary
  • 11.6.4.Recent developments
• 11.7.Suven Life Sciences Limited
  • 11.7.1.Company details
  • 11.7.2.Financial outlook
  • 11.7.3.Product summary
  • 11.7.4.Recent developments
• 11.8.Biophore India Pharmaceuticals Pvt Ltd
  • 11.8.1.Company details
  • 11.8.2.Financial outlook
  • 11.8.3.Product summary
  • 11.8.4.Recent developments
• 11.9.Rhyme Organics and Chemicals Ltd
  • 11.9.1.Company details
  • 11.9.2.Financial outlook
  • 11.9.3.Product summary
  • 11.9.4.Recent developments
• 11.10.Aktteva Biopharma LLP
  • 11.10.1.Company details
  • 11.10.2.Financial outlook
  • 11.10.3.Product summary
  • 11.10.4.Recent developments
• 11.11.Others

12.Conclusion

13.List of Abbreviations

14.Reference Links